Key facts
- It has raised $5.5M; the latest was Early Stage VC in Jun 2024.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, STIC Ventures, Kiwoom Investment, Schmidt (South Korea) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for HITS (Discovery Tools (Healthcare))
- ·The full record, as it builds
Funding rounds
No funding rounds for HITS (Discovery Tools (Healthcare)) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HITS (Discovery Tools (Healthcare))
Developer of a drug development cloud platform designed to connect artificial intelligence models with docking and molecular dynamics. The company's platform uses both physics-based computational methods and data-driven approaches to improve accessibility through the web, lower the entry barrier for experimental researchers with the process, and offer various software, such as docking, prediction of physicochemical properties, and molecular dynamics simulations, enabling researchers to accelerate the drug development process and introduce a new paradigm of drug discovery.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 31
- Website
- hits.ai/
- Ownership
- Privately Held (backing)
HITS (Discovery Tools (Healthcare)) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HITS (Discovery Tools (Healthcare)) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HITS (Discovery Tools (Healthcare)) in its N-PORT filings yet. We sweep new filings monthly.